keyword
MENU ▼
Read by QxMD icon Read
search

Glycopyrronium

keyword
https://www.readbyqxmd.com/read/27886854/efficacy-and-safety-of-indacaterol-glycopyrronium-in-japanese-patients-with-copd-pooled-analysis-of-shine-and-arise
#1
Kazuhisa Asai, Kazuto Hirata, Shu Hashimoto, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Kimitoshi Ikeda, Robert Fogel, Donald Banerji
BACKGROUND: To better evaluate the efficacy and safety of the indacaterol/glycopyrronium (IND/GLY) fixed-dose combination versus tiotropium in Japanese patients, a pooled data analysis was conducted from the SHINE and ARISE studies, which were part of the IND/GLY clinical trial program. METHODS: Japanese patients with moderate-to-severe COPD were included in the analysis. Efficacy in terms of pre-dose forced expiratory volume in one second (FEV1) at Week 12 and Week 24/26 (ARISE/SHINE) and FEV1 at 30min and 60min post-dose at Day 1, Week 12, and Week 24/26 was evaluated...
November 2016: Respiratory Investigation
https://www.readbyqxmd.com/read/27871302/glycopyrrolate-in-comparison-to-hyoscine-hydrobromide-and-placebo-in-the-treatment-of-hypersalivation-induced-by-clozapine-gothic1-study-protocol-for-a-randomised-controlled-feasibility-study
#2
Inti Qurashi, Simon Chu, Nusrat Husain, Richard J Drake, Imran Chaudhry, J F W Deakin
BACKGROUND: Clozapine is the only medication licensed for the treatment of resistant schizophrenia in the UK. Although efficacious, a common and unpopular side effect of clozapine treatment is clozapine-induced hypersalivation (CIH), which can contribute to non-adherence. The standard treatment for CIH in the UK is hyoscine hydrobromide but this may aggravate cognitive deficits in patients with schizophrenia while glycopyrrolate may be an effective alternative with a more tolerable side effect profile...
November 21, 2016: Trials
https://www.readbyqxmd.com/read/27853383/uk-specific-cost-effectiveness-of-tiotropium-olodaterol-fixed-dose-combination-versus-other-lama-laba-combinations-in-patients-with-copd
#3
Abigail Tebboth, Andrew Ternouth, Nuria Gonzalez-Rojas
OBJECTIVE: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinations in comparison with Spiolto(®) Respimat(®) (tiotropium + olodaterol fixed-dose combination [FDC]) for maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. METHODS: A previously published individual-level Markov model was adapted for the perspective of the UK health care system, in line with recommendations from the National Institute for Health and Care Excellence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27787709/muscarinic-receptor-antagonists
#4
Maria Gabriella Matera, Mario Cazzola
Parasympathetic activity is increased in patients with chronic obstructive pulmonary disease (COPD) and asthma and appears to be the major reversible component of airway obstruction. Therefore, treatment with muscarinic receptor antagonists is an effective bronchodilator therapy in COPD and also in asthmatic patients. In recent years, the accumulating evidence that the cholinergic system controls not only contraction by airway smooth muscle but also the functions of inflammatory cells and airway epithelial cells has suggested that muscarinic receptor antagonists could exert other effects that may be of clinical relevance when we must treat a patient suffering from COPD or asthma...
October 28, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27785010/efficacy-and-safety-of-indacaterol-glycopyrronium-in-japanese-patients-with-copd-a-subgroup-analysis-from-the-shine-study
#5
Shu Hashimoto, Hisataro Ikeuchi, Shujiro Murata, Tetsuji Kitawaki, Kimitoshi Ikeda, Donald Banerji
BACKGROUND: COPD-related deaths are increasing in Japan, with ~5.3 million people at risk. METHODS: The SHINE was a 26-week, multicenter, randomized, double-blind, parallel-group study that evaluated safety and efficacy of indacaterol (IND)/glycopyrronium (GLY) 110/50 μg once daily (od) compared with GLY 50 μg od, IND 150 μg od, open-label tiotropium (TIO) 18 μg od, and placebo. The primary end point was trough forced expiratory volume in 1 second (FEV1) at Week 26...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27730198/a-randomised-open-label-study-of-umeclidinium-versus-glycopyrronium-in-patients-with-copd
#6
Tara Rheault, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church, William A Fahy
This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease. This was a 12-week, multicentre, randomised, open-label, parallel-group study (Clinicaltrials.gov: NCT02236611). Patients were randomised 1:1 to umeclidinium 62.5 µg or glycopyrronium 50 µg administered via Ellipta or Breezhaler dry powder inhaler, respectively. The primary endpoint was trough forced expiratory volume in 1 s (FEV1) at day 85 in the per-protocol population...
April 2016: ERJ Open Research
https://www.readbyqxmd.com/read/27715335/efficacy-and-safety-of-indacaterol-glycopyrronium-ind-gly-versus-salmeterol-fluticasone-in-chinese-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-the-chinese-cohort-from-the-lantern-study
#7
Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Michael Humphries, Linda Wang, Francesco Patalano, Donald Banerji
Inhaled indacaterol/glycopyrronium fixed-dose combination (IND/GLY) is approved in over 80 countries, including the EU, Japan, Australia and Switzerland and the US. The LANTERN study evaluated the efficacy of IND/GLY compared with inhaled long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) or salmeterol/fluticasone (SFC) in patients with moderate-to-severe COPD with a history of ≤1 exacerbation in the previous year. Here we present the efficacy and safety of IND/GLY versus SFC in the Chinese cohort from the LANTERN study...
December 2016: COPD
https://www.readbyqxmd.com/read/27692151/computed-tomography-ct-assessed-bronchodilation-induced-by-inhaled-indacaterol-and-glycopyrronium-indacaterol-in-copd
#8
Kaoruko Shimizu, Ruriko Seto, Hironi Makita, Masaru Suzuki, Satoshi Konno, Yoichi M Ito, Rie Kanda, Emiko Ogawa, Yasutaka Nakano, Masaharu Nishimura
BACKGROUND: Our previous studies suggested that the site of bronchodilation on CT might differ between inhaled β2 agonists and inhaled anticholinergics in COPD. AIM: To assess and compare the bronchodilation effects of inhaled indacaterol and glycopyrronium/indacaterol by airway generation in large airways using CT. METHODS: CT scans at full inspiration and pulmonary function tests were done in 25 patients with moderate-severe COPD before and 4-5 weeks after daily inhalation of indacaterol and again another 4-5 weeks after inhalation of glycopyrronium/indacaterol...
October 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27598678/single-inhaler-triple-therapy-versus-inhaled-corticosteroid-plus-long-acting-%C3%AE-2-agonist-therapy-for-chronic-obstructive-pulmonary-disease-trilogy-a-double-blind-parallel-group-randomised-controlled-trial
#9
RANDOMIZED CONTROLLED TRIAL
Dave Singh, Alberto Papi, Massimo Corradi, Ilona Pavlišová, Isabella Montagna, Catherine Francisco, Géraldine Cohuet, Stefano Vezzoli, Mario Scuri, Jørgen Vestbo
BACKGROUND: Few data are available for the efficacy of "triple therapy" with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD). We designed this study to assess efficacy of single-inhaler combination of an extra fine formulation of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) in COPD compared with beclometasone dipropionate and formoterol fumarate (BDP/FF) treatment. METHODS: TRILOGY was a randomised, parallel group, double-blind, active-controlled study done in 159 sites across 14 countries...
September 3, 2016: Lancet
https://www.readbyqxmd.com/read/27579650/indacaterol-glycopyrronium-for-copd
#10
LETTER
Frits M E Franssen, Emiel F M Wouters, Lowie E G W Vanfleteren
No abstract text is available yet for this article.
September 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27579649/indacaterol-glycopyrronium-for-copd
#11
LETTER
Marco Contoli, Paolo Morelli, Alberto Papi
No abstract text is available yet for this article.
September 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27579648/indacaterol-glycopyrronium-for-copd
#12
LETTER
Samy Suissa
No abstract text is available yet for this article.
September 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27579647/indacaterol-glycopyrronium-for-copd
#13
LETTER
Jadwiga A Wedzicha, Donald Banerji, Claus F Vogelmeier
No abstract text is available yet for this article.
September 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27578477/duration-of-bronchoprotection-of-the-long-acting-muscarinic-antagonists-tiotropium-glycopyrronium-against-methacholine-induced-bronchoconstriction-in-mild-asthmatics
#14
Christianne M Blais, Beth E Davis, Donald W Cockcroft
UNLABELLED: The duration of bronchoprotection against methacholine-induced bronchoconstriction by long-acting muscarinic antagonists (LAMA's) in asthmatics and whether these drugs differ in their pharmacodynamic properties remain to be determined. The most recent published guidelines for methacholine challenge testing (MCT) suggest that LAMA's should be abstained from for 48 h prior to testing, perhaps one week in the case of tiotropium. The objectives were to determine and compare the duration of protection of a single dose of two different LAMA's, tiotropium and glycopyrronium, against methacholine-induced bronchoconstriction...
September 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27552524/formoterol-fumarate-glycopyrrolate-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#15
Dejan Radovanovic, Marco Mantero, Giuseppe Francesco Sferrazza Papa, Vincenzo Valenti, Stefano Aliberti, Fabiano Di Marco, Pierachille Santus
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is characterized by a high disability and increasing mortality. Bronchodilators are the cornerstone of pharmacological treatment in COPD, while therapeutic optimization with an improvement in symptoms and compliance represent the actual goals. This has led to the development of devices that combine different classes of inhalatory drugs. Recently, a novel combination of the long acting antimuscarinic agent glycopyrronium bromide and the beta2-agonist formoterol fumarate has been developed in a metered dose inhaler delivery system...
October 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/27516088/cost-effectiveness-of-the-long-acting-%C3%AE-2-adrenergic-agonist-laba-long-acting-muscarinic-antagonist-dual-bronchodilator-indacaterol-glycopyrronium-versus-the-laba-inhaled-corticosteroid-combination-salmeterol-fluticasone-in-patients-with-chronic-obstructive
#16
M Reza Maleki-Yazdi, Mathieu Molimard, Dorothy L Keininger, Jean-Bernard Gruenberger, Joao Carrasco, Claudia Pitotti, Elsa Sauvage, Sara Chehab, David Price
OBJECTIVE: The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who had a history of one or no exacerbations in the previous year, in Canada, France, Italy, and Portugal. METHODS: A patient-level simulation was developed to compare the costs and outcomes of IND/GLY versus SFC based on data from the LANTERN trial (NCT01709903)...
October 2016: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/27452453/triple-inhaled-therapy-for-chronic-obstructive-pulmonary-disease
#17
REVIEW
Paolo Montuschi, Mario Malerba, Giuseppe Macis, Nadia Mores, Giuseppe Santini
Combining individual drugs in a single inhaler is the most convenient way to deliver triple therapy. A long-acting muscarinic receptor antagonist (LAMA) added to an inhaled corticosteroid (ICS)/long-acting β2-adrenoceptor agonist (LABA) fixed-dose combination (FDC) can improve efficacy of pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD). New inhaled ICS/LABA/LAMA FDCs, including fluticasone furoate/vilanterol/umeclidinium, budesonide/formoterol/glycopyrronium and beclometasone/formoterol/glycopyrronium, are in Phase III of clinical development for COPD...
July 21, 2016: Drug Discovery Today
https://www.readbyqxmd.com/read/27418815/early-bronchodilator-action-of-glycopyrronium-versus-tiotropium-in-moderate-to-severe-copd-patients-a-cross-over-blinded-randomized-study-symptoms-and-pulmonary-function-in-the-morning
#18
Jose M Marin, Kai M Beeh, Andreas Clemens, Walter Castellani, Lennart Schaper, Dinesh Saralaya, Anthony Gunstone, Ricard Casamor, Konstantinos Kostikas, Maryam Aalamian-Mattheis
BACKGROUND: Morning symptoms associated with COPD have a negative impact on patients' quality of life. Long-acting bronchodilators with rapid onset may relieve patients' symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator profile of glycopyrronium (GLY) and tiotropium (TIO) during the first few hours after dosing in patients with moderate-to-severe COPD. METHODS: Patients were randomized (1:1) to receive either once-daily GLY (50 μg) or TIO (18 μg) and corresponding placebos in a cross-over design for 28 days...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27354818/cost-effectiveness-of-tiotropium-versus-glycopyrronium-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-in-canada-spain-sweden-and-the-uk
#19
Oskar Eklund, Faraz Afzal, Fredrik Borgström, Jason Flavin, Andrew Ternouth, Maria Eugenia Ojanguren, Carlos Crespo, Mike Baldwin
OBJECTIVES: Tiotropium (TIO), Spiriva® Handihaler®, is a well-established bronchodilator, LAMA (long acting muscarinic antagonist), for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). Clinical evidence from the SPARK trial suggests that TIO is superior to glycopyrronium (GLY), Seebri® Breezhaler®, in terms of severe exacerbations. This modeling study assessed the cost-effectiveness of TIO versus GLY for Canada (CAN), Spain (ESP), Sweden (SWE), and the UK, making use of this new clinical evidence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27301417/effects-of-indacaterol-glycopyrronium-qva149-on-lung-hyperinflation-and-physical-activity-in-patients-with-moderate-to-severe-copd-a-randomised-placebo-controlled-crossover-study-the-move-study
#20
Henrik Watz, Claudia Mailänder, Monika Baier, Anne Kirsten
BACKGROUND: Physical activity limitation is common in chronic obstructive pulmonary disease (COPD), and is associated with worse health status, and increased hospitalisation and mortality. Long-acting bronchodilators, either alone or in combination, have been shown to improve exercise intolerance. However, none of these studies were designed with physical activity as primary outcome. This study assessed the effect of indacaterol/glycopyrronium fixed dose combination (IND/GLY) 110/50 μg once daily (OD) versus placebo on lung hyperinflation (inspiratory capacity [IC]) and physical activity in patients with moderate-to-severe COPD...
2016: BMC Pulmonary Medicine
keyword
keyword
60123
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"